Annual report pursuant to Section 13 and 15(d)

Schedule II-Consolidated Valuation and Qualifying Accounts and Reserves

v3.24.1
Schedule II-Consolidated Valuation and Qualifying Accounts and Reserves
12 Months Ended
Dec. 31, 2023
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II-Consolidated Valuation and Qualifying Accounts and Reserves

BIOLASE, INC.

Schedule II — Consolidated Valuation and Qualifying Accounts and Reserves

For the Years Ended December 31, 2023, 2022, and 2021

(in thousands)

 

 

 

Balance at

 

 

Charges

 

 

 

 

 

 

 

 

 

Beginning

 

 

(Reversals) to Cost

 

 

 

 

 

Balance at

 

 

 

of Year

 

 

or Expenses

 

 

Deductions

 

 

End of Year

 

Year Ended December 31, 2021:

 

 

 

 

 

 

 

 

 

 

 

 

Allowance for doubtful accounts

 

$

4,017

 

 

$

(202

)

 

$

(1,661

)

 

$

2,154

 

Allowance for sales returns

 

 

262

 

 

 

 

 

 

 

 

 

262

 

Allowance for tax valuation

 

 

21,743

 

 

 

5,518

 

 

 

 

 

 

27,261

 

Year Ended December 31, 2022:

 

 

 

 

 

 

 

 

 

 

 

 

Allowance for doubtful accounts

 

$

2,154

 

 

$

(12

)

 

$

22

 

 

$

2,164

 

Allowance for sales returns

 

 

262

 

 

 

 

 

 

 

 

 

262

 

Allowance for tax valuation

 

 

27,261

 

 

 

(4

)

 

 

3,978

 

 

 

31,235

 

Year Ended December 31, 2023:

 

 

 

 

 

 

 

 

 

 

 

 

Allowance for doubtful accounts

 

$

2,164

 

 

$

(2,034

)

 

$

114

 

 

$

244

 

Allowance for sales returns

 

 

262

 

 

 

 

 

 

 

 

 

262

 

Allowance for tax valuation

 

 

31,235

 

 

 

(24

)

 

 

4,595

 

 

 

35,806